Pivotal readout
enGene to start detalimogene BLA by year-end after new LEGEND bladder cancer data
In the pivotal cohort of the phase 2 LEGEND trial in high-risk bladder cancer that no longer responds to BCG, 56% of 120 evaluable patients had a complete response, with a preliminary median duration of 10.1 months. Serious drug-related events hit 2% of patients. After meeting the FDA, enGene will begin its submission this year and aims to finish it by mid-2027.
- Drugdetalimogene voraplasmid
- CompanyenGene
- TargetInterleukin-12 receptor
- TargetRetinoic acid-inducible gene I protein
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.